Madrigal Reports Strong Rezdiffra Sales Nearing $1 Billion and Expands MASH Pipeline with Multiple New Programs

summarizeSummary

Madrigal Pharmaceuticals reported nearly $1 billion in Rezdiffra sales for its first full year and significantly expanded its MASH pipeline with new licensing agreements, reinforcing its market leadership and future growth strategy.

check_boxKey Events

• Strong Rezdiffra Sales Performance

  Reported fourth-quarter net sales of $321.1 million and full-year 2025 net sales of $958.4 million for Rezdiffra, its MASH treatment, in its first full year of launch.

• Significant Pipeline Expansion

  Licensed global rights to six preclinical siRNA programs and an exclusive global license for ervogastat, a Phase 2 oral DGAT-2 inhibitor, alongside an oral GLP-1 (MGL-2086), diversifying its MASH therapeutic portfolio.

• Positive Clinical Data for F4c MASH

  Presented two-year data from the NAFLD-1 trial's F4c cohort, showing Rezdiffra significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis.

• Solid Financial Position

  Ended 2025 with $988.6 million in cash, cash equivalents, restricted cash, and marketable securities, supported by a $500 million senior secured credit facility secured in July 2025.

auto_awesomeAnalysis

Madrigal Pharmaceuticals delivered a highly positive earnings report, showcasing robust commercial success for Rezdiffra, its flagship MASH treatment, with nearly $1 billion in sales during its first full year on the market. This strong performance is complemented by an aggressive and strategic expansion of its MASH pipeline, including licensing multiple preclinical siRNA programs, a Phase 2 DGAT-2 inhibitor (ervogastat), and an oral GLP-1 agonist. These moves signal a significant shift towards developing combination therapies and diversifying the company's future growth drivers beyond a single product. The positive two-year clinical data for Rezdiffra in compensated MASH cirrhosis (F4c) further strengthens its market position and potential. The company's solid cash position and recent credit facility provide ample resources for continued R&D and commercialization efforts. This filing indicates strong execution on both commercial and strategic fronts, positioning Madrigal as a leader in the MASH therapeutic space.